Identity
What is Tirzepatide?
A synthetic, acylated 39-residue peptide (development code LY3298176) that activates GIP and GLP-1 receptors.

Research reference · Weight & Metabolism
Tirzepatide is a dual GIP and GLP-1 receptor agonist and the active ingredient in two FDA-approved medicines, Mounjaro and Zepbound. Its trial record is one of the largest of any peptide in this library.
Published by Elevated Pharma ·
Identity
A synthetic, acylated 39-residue peptide (development code LY3298176) that activates GIP and GLP-1 receptors.
Research context
The SURPASS (type 2 diabetes) and SURMOUNT (obesity) phase 3 programs are published, including head-to-head trials against semaglutide, a weight-maintenance trial and a three-year diabetes-prevention analysis.
Evidence boundary
Approval and trial results apply to the approved products as labeled. They do not transfer to an unlabeled research material or another supplier’s product.
U.S. status · November 7, 2026
FDA-approved as Mounjaro (type 2 diabetes, including children 10 and older since late 2025) and Zepbound (chronic weight management and obstructive sleep apnea). FDA approved a multi-dose Zepbound KwikPen in February 2026.
Research updates
Dated developments for Tirzepatide, newest first. See all research updates.
Lilly presents TOGETHER-PsA, a phase 3b study of ixekizumab with tirzepatide in psoriatic arthritis with obesity.
Read the sourceKey studies
Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.
Search all 2,748 PubMed records for Tirzepatide · Counts and selections checked November 7, 2026.
Reference identifiers
Database identity describes the reference substance, not any specific material or lot.
Official & primary sources
Citation does not imply an Elevated Pharma partnership or endorsement.